Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 16/20 | 0.67 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1037464 | 0.89 | CYP11B2 (0.77) | CYP11B2CYP11B1CYP19A1KCNH2 | |
| SCHEMBL1041223 | 0.89 | CYP11B2 (0.64) | CYP11B2CYP11B1CYP19A1KCNH2CYP17A1 | |
| SCHEMBL1040222 | 0.87 | CYP11B2 (0.78) | CYP11B2CYP11B1CYP19A1KCNH2CYP17A1 | |
| SCHEMBL1039594 | 0.85 | CYP11B2 (0.74) | CYP11B2CYP11B1CYP19A1KCNH2CYP17A1 | |
| SCHEMBL1041285 | 0.84 | CYP11B2 (0.78) | CYP11B2CYP11B1CYP19A1KCNH2CYP17A1 | |
| SCHEMBL1036341 | 0.83 | CYP11B2 (0.93) | CYP11B2CYP11B1CYP19A1KCNH2 | |
| SCHEMBL13516464 | 0.83 | CYP11B2 (0.76) | CYP11B2CYP11B1CYP19A1KCNH2CYP17A1 | |
| SCHEMBL1039734 | 0.82 | CYP11B2 (0.77) | CYP11B2CYP11B1CYP19A1KCNH2 | |
| SCHEMBL1042026 | 0.80 | CYP11B2 (1.00) | CYP11B2CYP11B1CYP19A1 | |
| SCHEMBL1041113 | 0.80 | CYP11B2 (0.69) | CYP11B2CYP11B1CYP19A1KCNH2CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278969-B2 | Organic compounds | NOVARTIS AG (CH) | 2016-03-08 | — | — | US | disclosed |
| US-9278969-B2 | Organic compounds | NOVARTIS AG (CH) | 2016-03-08 | — | — | US | disclosed |
| US-9278969-B2 | Organic compounds | NOVARTIS AG (CH) | 2016-03-08 | — | — | US | disclosed |
| US-20140357621-A1 | Organic Compounds | NOVARTIS AG (CH) | 2014-12-04 | — | — | US | disclosed |
| US-20140357621-A1 | Organic Compounds | NOVARTIS AG (CH) | 2014-12-04 | — | — | US | disclosed |
| US-20140357621-A1 | Organic Compounds | NOVARTIS AG (CH) | 2014-12-04 | — | — | US | disclosed |
| EP-2256118-B1 | Condensed imidazolo derivatives for the inhibition of aromatase and the treatment of aldosterone related diseases | NOVARTIS AG (CH) | 2014-10-29 | — | — | EP | disclosed |
| EP-2256118-B1 | Condensed imidazolo derivatives for the inhibition of aromatase and the treatment of aldosterone related diseases | NOVARTIS AG (CH) | 2014-10-29 | — | — | EP | disclosed |
| US-8835646-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-09-16 | — | — | US | disclosed |
| US-8835646-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-09-16 | — | — | US | disclosed |
| EP-2270011-A1 | Condensed imidazolo derivatives for the inhibition of aromatase | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| EP-2270011-A1 | Condensed imidazolo derivatives for the inhibition of aromatase | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| EP-2256118-A1 | Condensed imidazolo derivatives for the inhibition of aromatase | Novartis AG (CH) | 2010-12-01 | — | — | EP | disclosed |
| EP-2256118-A1 | Condensed imidazolo derivatives for the inhibition of aromatase | Novartis AG (CH) | 2010-12-01 | — | — | EP | disclosed |
| EP-1919916-A1 | CONDENSED IMIDAZOLO DERIVATIVES FOR THE INHIBITION OF ALDOSTERONE SYNTHASE AND AROMATASE | Novartis AG (CH) | 2008-05-14 | — | — | EP | disclosed |
| US-20070049616-A1 | Organic compounds | RECORDATI AG (CH) | 2007-03-01 | — | — | US | disclosed |
| US-20070049616-A1 | Organic compounds | RECORDATI AG (CH) | 2007-03-01 | — | — | US | disclosed |
| US-20070049616-A1 | Organic compounds | RECORDATI AG (CH) | 2007-03-01 | — | — | US | disclosed |
| WO-2007024945-A1 | CONDENSED IMIDAZOLO DERIVATIVES FOR THE INHIBITION OF ALDOSTERONE SYNTHASE AND AROMATASE | NOVARTIS AG (CH) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007024945-A1 | CONDENSED IMIDAZOLO DERIVATIVES FOR THE INHIBITION OF ALDOSTERONE SYNTHASE AND AROMATASE | NOVARTIS AG (CH) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049616-A1 | Organic compounds | CYP19A1, CYP17A1, HSD17B11 | CYP11B2 14/4885CYP11B1 5/4885CYP19A1 1/4885 |
| US-20140357621-A1 | Organic Compounds | CYP19A1, CYP17A1, HSD17B11 | CYP11B2 14/4885CYP11B1 5/4885CYP19A1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.